Study Demonstrates Significant Reduction in Pleural Effusion Volume Using Pleural Dynamics’ ACES Fully-Implantable System
Pleural Dynamics, Inc. today announced positive results from a prospective, multicenter study evaluating its Automatic Continuous Effusion Shunt (ACES) device for the management of symptomatic recurrent pleural effusions. The study, presented at the CHEST 2025 Annual Meeting, demonstrated that implantation of the ACES device resulted in a 53% median reduction in pleural effusion volume at 30 days, with no adverse events related to fluid diversion to the abdomen reported.
